Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SF0166 in Neovascular AMD
NCT02914639Phase 2Completed
- Sponsor
- OcuTerra Therapeutics
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nesvategrast in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by OcuTerra Therapeutics. Primary endpoints: Number of Subjects With No Cells Observed Following Slit Lamp Examination at Week 8, Number of Subjects With Flare Observed Following Slit Lamp Examination at Week 8 and 14 more. Started Oct 2016; status: completed.
02
Drugs
nesvategrast
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02914639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914639.